{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T09:35:21Z","timestamp":1774690521216,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Technion, Israeli Institute of Technology, Haifa, Israel"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.urolonc.2017.12.007","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T01:08:15Z","timestamp":1514336895000},"page":"161.e1-161.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Overexpression of semaphorin 3A in patients with urothelial cancer"],"prefix":"10.1016","volume":"36","author":[{"given":"Zahava","family":"Vadasz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Rubinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Bejar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilla","family":"Sheffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarel","family":"Halachmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2017.12.007_bib1","first-page":"412","article-title":"Urine cytology and adjunct markers for detection and surveillance of bladder cancer","volume":"2","author":"Sullivan","year":"2010","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.urolonc.2017.12.007_bib2","first-page":"222","article-title":"Urine markers for detection and surveillance of bladder cancer","volume":"32","author":"Xylinas","year":"2014","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2017.12.007_bib3","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2214\/AJR.08.1351","article-title":"Cumulative radiation exposure and cancer risk estimates in emergency department patients undergoing repeat or multiple CT","volume":"192","author":"Griffey","year":"2009","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.urolonc.2017.12.007_bib4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2009.05.023","article-title":"Etiology of urethral stricture disease in the 21st century","volume":"182","author":"Lumen","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2017.12.007_bib5","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1242\/dev.105544","article-title":"Semaphorin signalling during development","volume":"141","author":"Jongbloets","year":"2014","journal-title":"Development"},{"key":"10.1016\/j.urolonc.2017.12.007_bib6","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/onc.2014.79","article-title":"Semaphorin 3A upregulates FOXO 3a-dependent MelCAM expression leading to attenuation of breast tumor growth and angiogenesis","volume":"34","author":"Mishra","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2017.12.007_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.4149\/neo_2013_087","article-title":"The predictive value of semaphorins 3 expression in biopsies for biochemical recurrence of patients with low- and intermediate-risk prostate cancer","volume":"60","author":"Li","year":"2013","journal-title":"Neoplasma"},{"key":"10.1016\/j.urolonc.2017.12.007_bib8","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1002\/eji.200535601","article-title":"Immunosuppressive role of semaphorin-3A on T cell proliferation is mediated by inhibition of actin cytoskeleton reorganization","volume":"36","author":"Lepelletier","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.urolonc.2017.12.007_bib9","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0961203311417034","article-title":"The involvement of immune semaphorins and neuropilin-1 in lupus nephritis","volume":"20","author":"Vadasz","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.urolonc.2017.12.007_bib10","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.4049\/jimmunol.0903527","article-title":"The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis","volume":"185","author":"Catalano","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.urolonc.2017.12.007_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nature11000","article-title":"Osteoprotection by semaphorin 3A","volume":"485","author":"Hayashi","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2017.12.007_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/hmg\/ddq468","article-title":"Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: implications for the aetiology of hypogonadotropic hypogonadism","volume":"20","author":"Cariboni","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.urolonc.2017.12.007_bib13","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/ATVBAHA.110.211920","article-title":"Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models","volume":"31","author":"Casazza","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.urolonc.2017.12.007_bib14","first-page":"7","article-title":"Semaphorin 3A suppresses tumor growth and metastasis in mice melanoma model","author":"Chakraborty","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2017.12.007_bib15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3892\/ol.2014.1920","article-title":"Significance of semaphorin-3A and MMP-14 protein expression in non-small cell lung cancer","volume":"7","author":"Zhou","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2017.12.007_bib16","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1002\/ijc.22949","article-title":"Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer","volume":"121","author":"M\u00fcller","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2017.12.007_bib17","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1038\/onc.2009.204","article-title":"Autocrine semaphorin 3A signaling promotes glioblastoma dispersal","volume":"28","author":"Bagci","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2017.12.007_bib18","doi-asserted-by":"crossref","first-page":"51733","DOI":"10.18632\/oncotarget.10104","article-title":"Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection","volume":"7","author":"Z.-Q.","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2017.12.007_bib19","first-page":"2","article-title":"Semaphorins in angiogenesis and tumor progression.","author":"Neufeld","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.urolonc.2017.12.007_bib20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neulet.2016.08.060","article-title":"Cancer pain relief achieved by disrupting tumor-driven semaphorin 3A signaling in mice","volume":"632","author":"Maeda","year":"2016","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.urolonc.2017.12.007_bib21","first-page":"8","article-title":"Semaphorin 3A is a new early diagnostic biomarker of experimental and pediatric acute kidney injury","author":"Jayakumar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2017.12.007_bib22","first-page":"10","article-title":"The involvement of immune semaphorins in the pathogenesis of inflammatory bowel diseases (IBDs)","author":"Vadasz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.urolonc.2017.12.007_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/jnen\/nlw003","article-title":"The axon guidance protein semaphorin 3A is increased in the motor cortex of patients with amyotrophic lateral sclerosis","volume":"75","author":"K\u00f6rner","year":"2016","journal-title":"J Neuropathol Exp Neurol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917306208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143917306208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:13:19Z","timestamp":1761041599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143917306208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S1078143917306208"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.12.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overexpression of semaphorin 3A in patients with urothelial cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2017.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}